» Articles » PMID: 32736646

Impact of Cardiovascular Involvement on the Clinical Course of Paediatric Mitochondrial Disorders

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2020 Aug 2
PMID 32736646
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary mitochondrial disorders (PMD) are rare conditions resulting in progressive multi-organ failure. Cardiovascular involvement (CVI) has been reported in paediatric patients. However, its age-related prevalence, clinical presentation and prognostic impact are unresolved. We detailed CVI in a cohort of children diagnosed with PMD over two decades at a tertiary referral centre.

Results: We enrolled 86 PMD patients (M/F = 30/56; mean age 6.4 ± 8.58 years). CVI was detected in 31 patients (36%), with mean age at onset of 5.7 ± 7.8 years including the pre- and neonatal phase in 14, often representing the first sign of PMD (42% of those with CVI). Heart disease resulted more common in males and in children with specific aetiologies (Barth, TMEM70 and MELAS syndromes). Hypertrophic, non-compaction and dilated cardiomyopathies were the prevalent disorders, although pulmonary arterial hypertension was also found. Adverse cardiac events (heart failure, resuscitated cardiac arrest, ICD/PM implantation, sudden death) occurred in 19% of children with CVI over a follow-up period of 5.4 ± 4.3 years. All-cause mortality was higher in patients with CVI compared to those without CVI (45.1% vs 21.8%; p < 0.01); female sex, age at onset < 5 years, acute heart failure at presentation and diabetes also proved independent predictors of outcome.

Conclusion: Cardiovascular involvement occurred in over one-third of children diagnosed with PMD, often at a very early age, and was associated with adverse prognosis. Final outcome of PMD-related CVI was influenced by the specific underlying aetiology, suggesting the need for tailored management of heart failure and sudden death prevention.

Citing Articles

Mitochondrial non-energetic function and embryonic cardiac development.

Shi J, Jin Y, Lin S, Li X, Zhang D, Wu J Front Cell Dev Biol. 2024; 12:1475603.

PMID: 39435335 PMC: 11491369. DOI: 10.3389/fcell.2024.1475603.


Variability of Clinical Phenotypes Caused by Isolated Defects of Mitochondrial ATP Synthase.

Tauchmannova K, Pecinova A, Houstek J, Mracek T Physiol Res. 2024; 73(Suppl 1):S243-S278.

PMID: 39016153 PMC: 11412354. DOI: 10.33549/physiolres.935407.


Nutritional Approach in Selected Inherited Metabolic Cardiac Disorders-A Concise Summary of Available Scientific Evidence.

Luca A, Paduret I, Tarca V, David S, Mindru D, Rosu S Nutrients. 2023; 15(22).

PMID: 38004189 PMC: 10675151. DOI: 10.3390/nu15224795.


Mitochondrial Cardiomyopathy Due to the Variant m.4300A>G Requires Comprehensive Clinical and Genetic Workup.

Finsterer J Radiol Cardiothorac Imaging. 2023; 5(4):e230144.

PMID: 37693190 PMC: 10485717. DOI: 10.1148/ryct.230144.


Recent Advances in Modeling Mitochondrial Cardiomyopathy Using Human Induced Pluripotent Stem Cells.

Pavez-Giani M, Cyganek L Front Cell Dev Biol. 2022; 9:800529.

PMID: 35083221 PMC: 8784695. DOI: 10.3389/fcell.2021.800529.


References
1.
Shinwari Z, Almesned A, Alakhfash A, Al-Rashdan A, Faqeih E, Al-Humaidi Z . The Phenotype and Outcome of Infantile Cardiomyopathy Caused by a Homozygous ELAC2 Mutation. Cardiology. 2017; 137(3):188-192. DOI: 10.1159/000465516. View

2.
Haack T, Kopajtich R, Freisinger P, Wieland T, Rorbach J, Nicholls T . ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. Am J Hum Genet. 2013; 93(2):211-23. PMC: 3738821. DOI: 10.1016/j.ajhg.2013.06.006. View

3.
Gibson K, Halliday J, Kirby D, Yaplito-Lee J, Thorburn D, Boneh A . Mitochondrial oxidative phosphorylation disorders presenting in neonates: clinical manifestations and enzymatic and molecular diagnoses. Pediatrics. 2008; 122(5):1003-8. DOI: 10.1542/peds.2007-3502. View

4.
Hildick-Smith G, Cooney J, Garone C, Kremer L, Haack T, Thon J . Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. Am J Hum Genet. 2013; 93(5):906-14. PMC: 3824126. DOI: 10.1016/j.ajhg.2013.09.011. View

5.
Garcia-Cazorla A, de Lonlay P, Nassogne M, Rustin P, Touati G, Saudubray J . Long-term follow-up of neonatal mitochondrial cytopathies: a study of 57 patients. Pediatrics. 2005; 116(5):1170-7. DOI: 10.1542/peds.2004-2407. View